AngioFlamma® 552
Product#: ARW1011
$939.52
Size of product (mg)
-
1 mg
-
5 mg
Availability:
Ships in 1-2 Weeks
AngioFlamma® 552
Cat. No. List below
Description
AngioFlamma® 552 is a cutting-edge angiogenesis imaging fluorescent probe designed for in vivo visualization of blood vessels, tumors, and angiogenesis. This probe combines the cyclic RGD (Arg-Gly-Asp) peptide with the Flamma® 552 fluorophore, making it an exceptional tool for studying vascular biology and tumor progression. The cyclic RGD peptide binds preferentially to αvβ3 integrin, a key biomarker in angiogenesis, which is highly expressed in many solid tumors but minimally present in normal epithelial and mature endothelial cells. Additionally, its ability to bind other integrins (αvβ5, α5β1, α6β4, α4β1, and αvβ6) enhances tumor uptake by increasing receptor population..
Key Features:
1. Fluorophore: Flamma® 552 with excitation/emission maxima at 550/565 nm
2. Molecular weight: 1272.53 g/mol
3. Appearance: Red liquid
4. Storage conditions: -20°C, protected from light
5. Integrin targeting: High specificity for αvβ3 integrin and additional binding to other integrins
Applications:
1. In vivo imaging of blood vessels and tumor vasculature
2. Angiogenesis research for cancer biology studies
3. Evaluation of anti-angiogenic therapies
4. Monitoring integrin expression in various tissues
5. Preclinical drug development and therapeutic efficacy testing
Advantages:
1. High specificity and affinity: Cyclic RGD peptide ensures selective targeting of αvβ3 integrin, a critical regulator of angiogenesis.
2. Enhanced tumor uptake: Binding to multiple integrins increases receptor availability, improving probe localization in tumors.
3. Bright fluorescence: The Flamma® 552 fluorophore provides strong red fluorescence for sensitive detection.
4. Non-invasive imaging: Enables real-time visualization of angiogenesis and tumor activity in living subjects without invasive procedures.
5. Versatile compatibility: Suitable for fluorescence imaging systems equipped with TRITC filter sets.
6. Quantitative analysis: Facilitates detailed assessment of angiogenic processes and integrin-related activity.
7. Broad utility: Applicable across diverse research areas including oncology, vascular biology, and drug discovery.
AngioFlamma® 552 is a powerful tool for researchers aiming to gain insights into the mechanisms of angiogenesis and tumor progression. Its high specificity, bright fluorescence signal, and ability to target multiple integrins make it an invaluable resource for preclinical imaging studies and translational research in cancer therapy.
Key Features:
1. Fluorophore: Flamma® 552 with excitation/emission maxima at 550/565 nm
2. Molecular weight: 1272.53 g/mol
3. Appearance: Red liquid
4. Storage conditions: -20°C, protected from light
5. Integrin targeting: High specificity for αvβ3 integrin and additional binding to other integrins
Applications:
1. In vivo imaging of blood vessels and tumor vasculature
2. Angiogenesis research for cancer biology studies
3. Evaluation of anti-angiogenic therapies
4. Monitoring integrin expression in various tissues
5. Preclinical drug development and therapeutic efficacy testing
Advantages:
1. High specificity and affinity: Cyclic RGD peptide ensures selective targeting of αvβ3 integrin, a critical regulator of angiogenesis.
2. Enhanced tumor uptake: Binding to multiple integrins increases receptor availability, improving probe localization in tumors.
3. Bright fluorescence: The Flamma® 552 fluorophore provides strong red fluorescence for sensitive detection.
4. Non-invasive imaging: Enables real-time visualization of angiogenesis and tumor activity in living subjects without invasive procedures.
5. Versatile compatibility: Suitable for fluorescence imaging systems equipped with TRITC filter sets.
6. Quantitative analysis: Facilitates detailed assessment of angiogenic processes and integrin-related activity.
7. Broad utility: Applicable across diverse research areas including oncology, vascular biology, and drug discovery.
AngioFlamma® 552 is a powerful tool for researchers aiming to gain insights into the mechanisms of angiogenesis and tumor progression. Its high specificity, bright fluorescence signal, and ability to target multiple integrins make it an invaluable resource for preclinical imaging studies and translational research in cancer therapy.
Specifications
- Fluorophore: Flamma® 552
- Application: Angiogenesis imaging
- Excitation/Emission Max.(nm): 550/565 nm
- Molecular weight: 1272.53 g/mol
- Appearance: Red Liquid
- Storage conditions: -20 ℃, protect from light
Table 1. List of Annexin V-Flamma® apoptosis detection kits
| Quick link (Cat.#) | Series | λEx (nm) | λEm (nm) | Common filter set | Excitation source | Size |
| ARW1025 | AngioFlamma® FAM | 492 | 519 | FITC | 488 nm | 0.5mg, 1mg, 5mg |
| ARW1011 | AngioFlamma® 552 | 550 | 565 | TRITC | 488, 532 nm | 0.5mg, 1mg, 5mg |
| ARR1001 | AngioFlamma® TAMRA | 543 | 575 | TRITC | 488, 532 nm | 0.5mg, 1mg, 5mg |
| ARW1415 | AngioFlamma® 581 | 581 | 596 | TRITC | 488, 532 nm | 0.5mg, 1mg, 5mg |
| ARW1215 | AngioFlamma® 648 | 648 | 663 | Cy®5 | 594, 633 nm | 0.5mg, 1mg, 5mg |
| ARW1501 | AngioFlamma® 675 | 675 | 691 | Cy®5.5 | 633, 680 nm | 0.5mg, 1mg, 5mg |
| ARW1301 | AngioFlamma® 749 | 749 | 774 | Cy®7 | 680 nm | 0.5mg, 1mg, 5mg |
| ARW1601 | AngioFlamma® 774 | 774 | 806 | Cy®7.5 | 785 nm | 0.5mg, 1mg, 5mg |
| ARO1601 | AngioFlamma® ICG | 785 | 821 | Cy®7.5 | 785 nm | 0.5mg, 1mg, 5mg |
Background
Integrins are heterodimeric transmembrane receptors for cell adhesion to extracellular matrix (ECM) proteins and play important roles in certain cell-cell adhesions. In addition, they make transmembrane connections to the cytoskeleton and activate many intracellular signaling pathways. Because of their role in tumor angiogenesis and progression, integrins have become important diagnostic and therapeutic targets. Integrin αvβ3 is generally expressed in low levels on the epithelial cells and mature endothelial cells, but it is highly expressed in many solid tumors. The αvβ3 levels correlate well with the potential for tumor metastasis and aggressiveness, which make it an important biological target for development of antiangiogenic drugs and molecular imaging probes for early tumor diagnosis. Cyclic tripeptide arginine-glycine-aspartate (RGD) is wellknown to bind preferentially to αvβ3 integrin with high affinity. Cyclic RGD is an effective ligand for tumor targeting since integrin αvβ3 is overexpressed not only on tumoral endothelium but also on various cancer cells. Thus, targeting tumor cells or tumor vasculature by RGD-based strategies is a promising approach for delivering anticancer drugs or diagnostic agents. Cyclic RGD peptides are also able to bind αvβ5, α5β1, α6β4, α4β1, and αvβ6 integrins, which may help enhance their tumor uptake due to the increased receptor population. BioActs developed AngioFlamma® series as effective fluorescent probes for the detection of angiogenesis and tumor cells. The probes are made up of various fluorophores conjugated cyclic RGD. We offer AngioFlamma® series as in vivo fluorescent probes for imaging of blood vessels, tumors and angiogenesis.
Integrins are heterodimeric transmembrane receptors for cell adhesion to extracellular matrix (ECM) proteins and play important roles in certain cell-cell adhesions. In addition, they make transmembrane connections to the cytoskeleton and activate many intracellular signaling pathways. Because of their role in tumor angiogenesis and progression, integrins have become important diagnostic and therapeutic targets. Integrin αvβ3 is generally expressed in low levels on the epithelial cells and mature endothelial cells, but it is highly expressed in many solid tumors. The αvβ3 levels correlate well with the potential for tumor metastasis and aggressiveness, which make it an important biological target for development of antiangiogenic drugs and molecular imaging probes for early tumor diagnosis. Cyclic tripeptide arginine-glycine-aspartate (RGD) is wellknown to bind preferentially to αvβ3 integrin with high affinity. Cyclic RGD is an effective ligand for tumor targeting since integrin αvβ3 is overexpressed not only on tumoral endothelium but also on various cancer cells. Thus, targeting tumor cells or tumor vasculature by RGD-based strategies is a promising approach for delivering anticancer drugs or diagnostic agents. Cyclic RGD peptides are also able to bind αvβ5, α5β1, α6β4, α4β1, and αvβ6 integrins, which may help enhance their tumor uptake due to the increased receptor population. BioActs developed AngioFlamma® series as effective fluorescent probes for the detection of angiogenesis and tumor cells. The probes are made up of various fluorophores conjugated cyclic RGD. We offer AngioFlamma® series as in vivo fluorescent probes for imaging of blood vessels, tumors and angiogenesis.
Figure 1. Breast cancer cell imaging using AngioFlamma® 675
In vivo Imaging protocol
1. Preparation of Xenograft tumor model
① MDA-MB-231 human breast cancer cells (1.0 x 107) are injected subcutaneously on the female nude mouse shoulder.
② After the tumor cells have grown to about 50-80 mm3, administer the drug.
2. Injection and Fluorescence imaging
① Fluorescence imaging would be performed up to 24 hours after injection using the optical imaging system.
② Prepared mice is injected intravenously with 100 μg / 200 μL of AngioFlamma® series and images will be taken at appropriate time interval.
① MDA-MB-231 human breast cancer cells (1.0 x 107) are injected subcutaneously on the female nude mouse shoulder.
② After the tumor cells have grown to about 50-80 mm3, administer the drug.
2. Injection and Fluorescence imaging
① Fluorescence imaging would be performed up to 24 hours after injection using the optical imaging system.
② Prepared mice is injected intravenously with 100 μg / 200 μL of AngioFlamma® series and images will be taken at appropriate time interval.
Citation & Reference
- Yumin Zheng. FITC-Conjugated Cyclic RGD Peptides as Fluorescent Probes for Staining Integrin αvβ3/αvβ5 in Tumor Tissues. Bioconjug Chem 25.1 (2014): 1925-41.
- Dongfang Yue. Biomarker-targeted fluorescent probes for breast cancer imaging. Chinese Chemical Letters 29.5 (2018): 648-656.
